Fred Hochberg, MD
Fred Hochberg, MD, is an authority on lymphoma affecting the nervous system and was responsible for the current curative use of high dose methotrexate to cure this disease. In addition, he performed the seminal studies that linked lymphoma to viral infection, and explored the use of high dose chemotherapy with autologous bone marrow transplantation for brain tumors and the local administration of chemotherapy by arterial infusion. He also established the neuro-oncology unit at the Harvard Medical School Massachusetts General Hospital, whose unit today is one of the leading diagnostic and therapeutic programs in the world. As an attending neurologist there, he pioneered many of the Phase 1 and Phase 2 trials for cancer of the brain. Dr. Hochberg has had continuous National Institutes of Health (NIH) program support for over 30 years, including 18 years as the principal investigator of projects designed to provide herpes gene therapy for neurologic cancers. For the past six years, he has received NIH program project and director's award funding to develop exosome-based diagnostics of brain diseases. Currently Dr. Hochberg is a visiting professor of neurosurgery at the University of California at San Diego.
Vice president & Treasurer
Ken Cummins was general counsel to a NYSE corporation for 20 years and counsel to a NASDAQ corporation for approximately 12 years. He focuses on corporate/business law and he has experience in various areas pertaining to intellectual property. In private practice, Ken advises and serves as general counsel to several privately held companies. He is a graduate of Colgate University (AB) and Boston University School of Law (JD)